Inovio Pharmaceuticals (INO) volatility flat into U.S. FDA placed a clinical hold proposed phase III clinical program for VGX-3100.

October 24, 2016 9:18 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Inovio Pharma (NASDAQ: INO) October put option implied volatility is at 66, January is at 64; compared to its 52-week range of 48 to 114 into the U.S. FDA placed a clinical hold on its proposed phase III clinical program for VGX-3100.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Related Entities

Options

Add Your Comment